Hormonal IUD for Heavy Periods: Four ECLIPSE Checks

When heavy periods interrupt work, sleep or leaving the house, a treatment discussion needs more than a promise of lighter flow. Ask what improvement was measured, how long it lasted and how the treatment fits your plans.

Check the comparator

ECLIPSE randomized 571 women aged 25–50 to Mirena or usual medicines, including tranexamic acid, mefenamic acid and hormonal options. Planned pregnancy within five years excluded participation.¹

The comparator was not one specified tablet. Tell your clinician which treatments you have tried, what happened while taking them and whether contraception is part of the decision.

NIHR¹ funded the trial; two authors disclosed Bayer fees outside the work.¹

Check what improved

The MMAS measured bleeding’s impact on daily life, from 0–100, higher being better. Mirena’s average advantage over two years was 13.4 points, 95% CI 9.9–16.9.¹

Those points are not a percentage reduction in blood loss. Describe a task the bleeding prevents: completing a shift, sleeping without changing protection or taking a bus ride. Ask how you and the clinician will decide whether treatment has helped that task.

Check later follow-up

At five years, 424/571 responded. The difference was 3.9 points, 95% CI −0.6–8.3, not statistically significant. Many switched or stopped treatment; 115 nonbleeding respondents were assigned maximum scores.¹

This does not establish equivalence; later care could change.

Ten-year follow-up was observational, with 206 respondents.²

Before choosing, ask what happens if bleeding remains unacceptable, you want removal or your pregnancy plans change. Put the review date and contact route on your treatment plan.

Check current use

UK NICE³ guidance considers an LNG-IUS first for heavy bleeding with no identified pathology, fibroids under 3 cm that do not distort the uterine cavity, or suspected or diagnosed adenomyosis.³ Ask which description fits your assessment.

NICE³ advises discussing early bleeding changes and allowing at least six cycles to see benefit.³ Our hormonal IUD bleeding guide covers changes that need review; contact the clinic immediately for severe pain or fever soon after insertion.⁴

The current US Mirena label permits heavy-bleeding treatment for five years in women choosing intrauterine contraception, versus eight years for contraception. Replacement is due at five years if heavy-bleeding treatment is still needed.⁴

Contraindications include unexplained uterine bleeding, current or past breast cancer and cavity-distorting uterine abnormalities.⁴ Bring previous diagnoses and investigation results to the fitting discussion. Confirm the device name, insertion date, treatment purpose and replacement date in writing.

Period, Handled includes “What the Options Are,” with pregnancy wishes, other symptoms and treatment preferences to prepare before a visit. Use that section to organize your questions. See the book.